LFAs now challenge this paradigm: graphene oxide-based LFAs detect epidermal growth factor receptor mutations in ctDNA from lung cancer patients with sensitivities comparable to digital PCR but at a fraction of the cost, while exosome-targeting LFAs quantify cancer-derived biomarkers in minutes rather than hours [139]. The gene discussed is EGFR; the disease is cancer.